瑞舒伐他汀与阿托伐他汀对稳定型心绞痛患者影响的对比研究  

Comparative Study for Impact on Stable Angina Pectoris between Rosuvastatin and Atorvastatin

作　　者：周杨[1] 苏婷[1] 张艳敏[1] 杨红妮[1] 徐红[1] ZHOU Yang;SU Ting;ZHANG Yan-min;YANG Hong-ni;XU Hong(Geriatric Medicine Center,the People's Hospital of Xinjiang Uygur Autonomous Region,Urumqi 830001,China)

机构地区：[1]新疆维吾尔自治区人民医院老年医学中心,新疆维吾尔自治区乌鲁木齐市830001

出　　处：《实用心脑肺血管病杂志》2018年第2期51-54,共4页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

基　　金：新疆维吾尔自治区自然科学基金资助项目(2014211C117);新疆维吾尔自治区人民医院院内科研项目(20150203)

摘　　要：目的比较瑞舒伐他汀与阿托伐他汀对稳定型心绞痛(SAP)患者的影响。方法选取2015年6月—2016年6月新疆维吾尔自治区人民医院心内科收治的SAP患者100例,采用随机数字表法分为瑞舒伐他汀组与阿托伐他汀组,每组50例。在常规治疗基础上,瑞舒伐他汀组患者予以瑞舒伐他汀治疗,阿托伐他汀组患者予以阿托伐他汀治疗;两组患者均连续治疗4周。比较两组患者降脂效果,治疗前后超敏C反应蛋白(hs-CRP)、白介素6(IL-6)、同型半胱氨酸(Hcy)水平及血管内皮细胞功能指标,并观察两组患者治疗期间不良反应发生情况。结果瑞舒伐他汀组患者降脂效果优于阿托伐他汀组(P<0.05)。治疗前两组患者hs-CRP、IL-6、Hcy水平比较,差异无统计学意义(P>0.05);治疗后瑞舒伐他汀组患者hs-CRP、IL-6、Hcy水平低于阿托伐他汀组(P<0.05)。治疗前两组患者脉压、臂踝脉搏波传导速度(ba PWV)、血流依赖性舒张功能(FMD)比较,差异无统计学意义(P>0.05);治疗后两组患者脉压比较,差异无统计学意义(P>0.05);治疗后瑞舒伐他汀组患者ba PWV低于阿托伐他汀组,FMD高于阿托伐他汀组(P<0.05)。两组患者治疗期间不良反应发生率比较,差异无统计学意义(P>0.05)。结论与阿托伐他汀相比,瑞舒伐他汀对SAP患者的降脂效果较好,并可更有效地降低hs-CRP、IL-6、Hcy水平,改善患者血管内皮细胞功能,且安全性较高。Objective To compare the impact on stable angina pectoris between rosuvastatin and atorvastatin.Methods From June 2015 to June 2016,a total of 100 patients with stable angina pectoris were selected in the Department of Cardiology,the People's Hospital of Xinjiang Uygur Autonomous Region,and they were divided into A group and B group according to random number table,each of 50 cases.Based on conventional treatment,patients in A group received rosuvastatin,while patients in B group received atorvastatin;both groups continuously treated for 4 weeks.Lipid-lowering effect,hs-CRP,IL-6,Hcy and index of vascular endothelial cell function before and after treatment were compared between the two groups,and incidence of adverse reactions during treatment was observed.Results Lipid-lowering effect in A group was statistically significantly better than that in B group(P<0.05).No statistically significant differences of hs-CRP,IL-6 or Hcy was found between the two groups before treatment(P>0.05),while hs-CRP,IL-6 and Hcy in A group were statistically significantly lower than those in B group after treatment(P<0.05).No statistically significant differences of pulse pressure,baPWV or FMD was found between the two groups before treatment(P>0.05),nor was pulse pressure between the two groups after treatment(P>0.05);after treatment,baPWV in A group was statistically significantly lower than that in B group,while FMD in A group was statistically significantly higher than that in A group(P<0.05).No statistically significant differences of incidence of adverse reactions was found during the treatment(P>0.05).Conclusion Compared with atorvastatin,rosuvastatin has better lipid-lowering effect,can more effectively reduce the hs-CRP,IL-6 and Hcy,improve the vascular endothelial cell function,with higher safety.

关 键 词：心绞痛 稳定型 瑞舒伐他汀 阿托伐他汀 疗效比较研究 

分 类 号：R541.4[医药卫生—心血管疾病]